Thus, the combining blockade of RSK2 and AKT has more robust molecular effects on HMCLs, raising the expectation for the universal efficacy on myeloma cells of diverse molecular features from different patients. This evidence concerns the gene RPS6KA3 and plasma cell myeloma.